{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:48:35Z","timestamp":1785757715582,"version":"3.56.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors have changed the treatment landscape for gastric and gastroesophageal junction adenocarcinoma, yet durable benefit remains uneven across biomarker-defined groups. PD-L1 combined positive score, MSI\/dMMR, tumor mutational burden, EBV status, HER2, and CLDN18.2 guide treatment eligibility, but they do not explain why effector immunity succeeds in one lesion and fails in another. This narrative review uses spatial immune niches as a framework for interpreting immunotherapy resistance in gastric cancer. These niches are tissue compartments in which malignant-cell states, effector-cell access, tertiary lymphoid structures, cancer-associated fibroblasts, tumor-associated macrophages, extracellular matrix, vascular function, and metastatic-site ecology jointly shape response. We synthesize evidence from clinical trials, single-cell and spatial multi-omics, multiplex immunohistochemistry and immunofluorescence, digital pathology, and translational biomarker studies. The review highlights clinically relevant niche states, including lymphoid-organized inflamed, inflamed-but-suppressed, stromal-excluded, myeloid-dominant, vascular\/hypoxic, target-antigen-associated, and peritoneal metastatic niches. It further discusses how compact spatial assays could refine patient selection and support niche-matched combination strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1905211","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:26:13Z","timestamp":1785756373000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial immune niches in gastric cancer immunotherapy resistance: mechanisms and translational implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziqiang","family":"Ling","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhe","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology III, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botao","family":"Yuan","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gao","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology III, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"Bmj"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1038\/s41467-026-68612-z","article-title":"A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region","volume":"17","author":"Gao","year":"2026","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332901","article-title":"Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages","volume":"74","author":"Lee","year":"2025","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009243","article-title":"Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer","volume":"12","author":"Groen-van Schooten","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2026.152495","article-title":"Targeting TREM2(+)tumor-associated macrophages reactivates antitumor immunity and improves anti-PD-1 efficacy in gastric cancer","volume":"53","author":"Xu","year":"2026","journal-title":"Semin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0605","article-title":"Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution","volume":"15","author":"Ma","year":"2025","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1767512","article-title":"Spatial multi-omics technologies in gastric cancer: applications and advances","volume":"17","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70775","article-title":"Mapping immunity with cutting-edge spatial biology and tissue cytometry innovations","volume":"7","author":"C\u00e1rdenas-Piedra","year":"2026","journal-title":"MedComm (2020)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10495-026-02287-1","article-title":"Spatially defined danger zone shapes gastric cancer progression through CCDC80(+) fibroblast-induced CD8(+) T cell dysfunction","volume":"31","author":"Mo","year":"2026","journal-title":"Apoptosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2024.08.007","article-title":"Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases","volume":"167","author":"Zhao","year":"2024","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","article-title":"Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618591","article-title":"Identification of a stromal immunosuppressive barrier orchestrated by SPP1(+)\/C1QC(+) macrophages and CD8(+) exhausted T cells driving gastric cancer immunotherapy resistance","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12967-025-06070-9","article-title":"Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011080","article-title":"Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer","volume":"13","author":"Yu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009603","article-title":"Intratumoral CXCL13(+) CD160(+) CD8(+) T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1186\/s12967-024-05867-4","article-title":"Association of PD-1\u2009+\u2009Treg\/PD-1\u2009+\u2009CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-3071","article-title":"Serglycin drives LAG3+ Treg differentiation and immunosuppression in gastric cancer","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1787060","article-title":"The tumor microenvironment shapes gastric cancer progression by coordinating immune suppression and metabolic reprogramming","volume":"17","author":"Jiao","year":"2026","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12943-024-02092-x","article-title":"Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1\u2009+\u2009antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics","volume":"23","author":"Cousin","year":"2024","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1847526","article-title":"Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host","volume":"17","author":"Ismaili","year":"2026","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09402-3","article-title":"NCAPD2 modulates MHC-I antigen presentation via the PI3K\/AKT axis to drive metastatic progression in gastric cancer","volume":"71","author":"Luo","year":"2026","journal-title":"Dig Dis Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2026.06.006","article-title":"JAK2 degradation by strebloside dismantles PD-L1-mediated immune evasion in EBV-associated gastric cancer","volume":"295","author":"Yang","year":"2026","journal-title":"Transl Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10120-023-01364-7","article-title":"Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer","volume":"26","author":"Choo","year":"2023","journal-title":"Gastric Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3390\/cancers17142407","article-title":"PD-1-Positive CD8+ T cells and PD-1-Positive FoxP3+ cells in tumor microenvironment predict response to neoadjuvant chemoimmunotherapy in gastric cancer patients","volume":"17","author":"Tashireva","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1823308","article-title":"Characterization of the tumor microenvironment in locally advanced gastric cancer and identification of spatially predictive biomarkers associated with beneficial neoadjuvant immunochemotherapy","volume":"17","author":"Xu","year":"2026","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-024-02085-w","article-title":"Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2804","article-title":"The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer","volume":"76","author":"Jiang","year":"2024","journal-title":"IUBMB Life"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3231","article-title":"Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment","volume":"26","author":"Sathe","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-025-06376-8","article-title":"Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1186\/s12885-026-15647-6","article-title":"Spatial atlas of gastric cancer reveals macrophage-driven stromal activation via ICAM1+ smooth muscle cells","volume":"26","author":"Cheng","year":"2026","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672312","article-title":"Pan-cancer convergence of tumour-immune microenvironment motifs revealed by CyTOF and imaging mass cytometry","volume":"16","author":"Vall\u00e9e","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mcb.2024.10.014","article-title":"Multidimensional profiling of cancer microenvironments in FFPE tissues by imaging mass cytometry","volume":"191","author":"Ijsselsteijn","year":"2025","journal-title":"Methods Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001834","article-title":"Digital assessment of tertiary lymphoid structures and therapeutic responses in gastric cancer: a multicentric retrospective study","volume":"110","author":"Chen","year":"2024","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-1793","article-title":"Artificial intelligence and multimodality data integration decipher tertiary lymphoid structure maturity in gastric cancer","volume":"85","author":"Wu","year":"2025","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010041","article-title":"Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy","volume":"12","author":"Ji","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/po.24.00230","article-title":"PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-644","article-title":"Intratumoral CD8(+) T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study","volume":"13","author":"Tong","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1713267","article-title":"Integrative single-cell, spatial, and bulk transcriptomics reveal an FMR1-FTO axis linked to the immune-excluded phenotype in gastric cancer","volume":"17","author":"Mao","year":"2026","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-025-03889-3","article-title":"Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer","volume":"23","author":"Xie","year":"2025","journal-title":"BMC Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.10.022","article-title":"Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+) tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy","volume":"166","author":"Hu","year":"2024","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1820652","article-title":"Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making","volume":"17","author":"Jiang","year":"2026","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ccell.2026.01.015","article-title":"Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer","volume":"44","author":"Zhao","year":"2026","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12943-025-02490-9","article-title":"Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41698-025-00967-w","article-title":"Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer","volume":"9","author":"Qiu","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01572-9","article-title":"SUSD2(+) cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy","volume":"28","author":"Su","year":"2025","journal-title":"Gastric Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03290-0","article-title":"Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer","volume":"134","author":"Luo","year":"2026","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010455","article-title":"Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer","volume":"13","author":"Kim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-25-0625","article-title":"Distinct spatially resolved tumor microenvironment trajectories define benefit from ramucirumab plus pembrolizumab in refractory PD-L1+ gastric cancer","volume":"14","author":"Lim","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-73","article-title":"Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study","volume":"14","author":"Xu","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00748","article-title":"Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0630","article-title":"Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials","volume":"28","author":"Yukami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001281","article-title":"Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study","volume":"110","author":"Yu","year":"2024","journal-title":"Int J Surg"},{"key":"B64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12957-026-04321-7","article-title":"Multi-omics exploration of hypoxia in gastric cancer","volume":"24","author":"Zhu","year":"2026","journal-title":"World J Surg Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08976-8","article-title":"Beyond a waste product: lactate as a master metabolite dictating anti-tumor T-cell fate","author":"Dai","year":"2026","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116863","article-title":"Activated CD38(+) mast cells promote gastric cancer progression by suppressing CD8(+) T cell cytotoxic activity through adenosine metabolism","volume":"45","author":"Zhao","year":"2026","journal-title":"Cell Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10564","article-title":"CDKN2A mRNA over-expression is associated with CD8+ T cell exclusion and IDO1-mediated adaptive immune resistance in gastric adenocarcinoma","volume":"6","author":"Lehrer","year":"2026","journal-title":"Cancer Diagn Progn"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.11.009","article-title":"PRDM15 inhibits responses of tissue-resident memory T cells by activating PVR\/TIGIT axis to mediate gastric cancer immunosuppression","author":"Zhang","year":"2025","journal-title":"J Adv Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-026-03703-9","article-title":"Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3(+)TAMs infiltration","volume":"45","author":"Zhou","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113871","article-title":"Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer","volume":"28","author":"Digomann","year":"2025","journal-title":"iScience"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04406-z","article-title":"CD90 mediates gastric cancer immune evasion though regulating IGF2BP2 to stabilize the m6A-CD47\/SIRP\u03b1 axis","author":"Liu","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-024-03667-9","article-title":"Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B73","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12967-024-05503-1","article-title":"Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-026-04370-0","article-title":"Therapeutic potential of targeting macrophage polarization in metastatic gastric cancer: a review on core mechanisms and clinical progress","author":"Gong","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2023.03.008","article-title":"Single-cell profiling of tumor immune microenvironment reveals immune irresponsiveness in gastric signet-ring cell carcinoma","volume":"165","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2026.02.09","article-title":"Refined immune-based molecular subtypes of gastric cancer: integrating mismatch repair status and tumor microenvironment for enhanced immunotherapy prediction","volume":"38","author":"Shen","year":"2026","journal-title":"Chin J Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ol.2026.15472","article-title":"Immune microenvironment and treatment response of dMMR gastric cancer: heterogeneity and implications for immunotherapy","volume":"31","author":"Wang","year":"2026","journal-title":"Oncol Lett"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2024.01.043","article-title":"Immune landscape of Epstein-Barr virus-associated gastric cancer: analysis from a Western academic institution","volume":"296","author":"Yee","year":"2024","journal-title":"J Surg Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0000000000001321","article-title":"Exploring the immune microenvironment for predicting immunotherapy efficacy in Epstein-Barr virus-associated gastric cancer","volume":"34","author":"Cho","year":"2026","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1674","article-title":"Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial","volume":"14","author":"Zhao","year":"2024","journal-title":"Clin Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508433","article-title":"Three-year follow-up of neoadjuvant tislelizumab with chemotherapy in locally advanced gastric and gastroesophageal junction adenocarcinoma: revealing cancer-associated fibroblast heterogeneity corresponding to PD-1 blockade efficacy","volume":"13","author":"Lin","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1186\/s12885-025-14805-6","article-title":"The immune signatures predict gastric\/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0386","article-title":"Advances and challenges in gastric cancer testing: the role of biomarkers","volume":"22","author":"Sun","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405485","article-title":"PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET","volume":"15","author":"Ibrahim","year":"2024","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-16298-3","article-title":"Clinicopathological features and immune checkpoint expression patterns in dMMR early gastric cancer: a retrospective pilot study","author":"Yokotani","year":"2026","journal-title":"BMC Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-05006-4","article-title":"A 3D pooled PBMC-organoid co-culture platform for profiling immune susceptibility and PD-1 blockade response in gastric cancer","author":"Mun","year":"2026","journal-title":"BMC Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3528","article-title":"Determinants of response to sequential pembrolizumab with trastuzumab plus platinum\/5-FU in HER2-positive gastric cancer: a phase II chemoimmunotherapy trial","volume":"31","author":"Lim","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-026-02577-x","article-title":"Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer","volume":"25","author":"Peng","year":"2026","journal-title":"Mol Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbaf038","article-title":"Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial","volume":"9","author":"Zhang","year":"2026","journal-title":"Precis Clin Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","article-title":"Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer","volume":"20","author":"Jia","year":"2022","journal-title":"BMC Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0204","article-title":"ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61121-x","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1905211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:26:14Z","timestamp":1785756374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1905211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2026.1905211"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1905211","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1905211"}}